Rhythm Adds $8M to Cap Series B at $33M

Biopharma startup Rhythm has closed on an additional $8 million in Series B financing to cap the round at $33 million. The newest infusion comes from Pfizer Venture Investments, the venture capital arm of Pfizer. Pfizer joins existing investors MPM Capital, New Enterprise Associates, Third Rock Ventures, and Ipsen. The money will go toward development of the company’s “small-peptide therapeutics” for metabolic diseases.

North AmericaUSBriefs